STAT3 (phospho-Ser727) Antibody
- Known as:
- STAT3 (phosphorilated-Ser727) Antibody
- Catalog number:
- abx000188
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- STAT3 (phospho-Ser727) Antibody
Related genes to: STAT3 (phospho-Ser727) Antibody
- Gene:
- STAT3 NIH gene
- Name:
- signal transducer and activator of transcription 3
- Previous symbol:
- -
- Synonyms:
- APRF
- Chromosome:
- 17q21.2
- Locus Type:
- gene with protein product
- Date approved:
- 1995-11-08
- Date modifiied:
- 2019-04-23
Related products to: STAT3 (phospho-Ser727) Antibody
Related articles to: STAT3 (phospho-Ser727) Antibody
- To identify the core acupoint prescription and Kellgren-Lawrence (K-L) grade-dependent compatibility patterns of acupuncture for KOA through complex network analysis, and to predict the potential molecular mechanisms underlying the core prescription via network pharmacology. - Source: PubMed
Publication date: 2026/09/01
Zhang DanningYang ShuangxinLin XingxingZhang KaixuanDong Baoqiang - Plasma cell mastitis (PCM) is a predominant form of non-lactational mastitis with an increasing incidence worldwide. The condition is characterized by a complex pathogenesis, difficulties in differential diagnosis, and a high rate of recurrence, thereby presenting significant challenges in clinical management. Conventional Western medicine is limited by high postoperative recurrence, difficulty in distinguishing PCM from breast cancer, and unsatisfactory long-term efficacy of single anti-inflammatory or hormone therapy. Against these clinical bottlenecks, Traditional Chinese medicine (TCM) shows unique advantages and accumulated extensive clinical experience for the treatment of PCM. This review systematically delineates the epidemiological characteristics and key pathophysiological mechanisms, including activation of the IL-6/STAT3 signaling pathway, immune cell dysregulation, autoimmune responses, distinctive plasma cell infiltration, and diagnostic methodologies such as imaging techniques, histopathological examination as the diagnostic gold standard, and emerging biomarkers. In addition, the theoretical foundations, contemporary pharmacological mechanisms, and clinical applications of comprehensive TCM therapy for PCM are summarized. Evidence indicates that TCM interventions, guided by syndrome differentiation and targeting liver qi stagnation, phlegm-stasis congealing, and heat-toxin accumulation, exert therapeutic effects by modulating inflammatory signaling pathways, correcting immune dysfunction, and restoring the mammary gland microecological balance. Clinical trials have demonstrated that combining TCM with surgical procedures or western medical treatments significantly improves clinical outcomes, reduces inflammatory mediator levels, and lowers recurrence rates. However, there remains a need for standardization in TCM syndrome differentiation, therapeutic evaluation criteria, and high-quality randomized controlled trials. In summary, integrated TCM therapy constitutes a safe and effective approach for managing PCM, and further rigorous research is warranted to enhance its clinical application and facilitate international recognition of TCM in PCM treatment. - Source: PubMed
Publication date: 2026/09/01
Kong XiangdingLiu ChangZhang AilingWang KuanyuWang LiweiChen HaoranXu Guijuan - Wuwei Huanglian Wan (WWHLW) is a traditional Tibetan medicine formula developed by Tibetan physician Takpe Pingcuo and officially documented in the Ministry of Health Drug Standards for Tibetan Medicines (Volume I, 1995). It has long been used for the treatment of gastrointestinal disorders, particularly conditions associated with gastrointestinal discomfort and inflammation. Given the overlap between its traditional indications and the clinical manifestations of H. pylori-associated gastritis (HAG), WWHLW represents a promising candidate for the management of H. pylori infection and related gastric inflammation. In addition, several constituent herbs of WWHLW have demonstrated anti-H. pylori and anti-inflammatory activities, providing a pharmacological basis for further investigating its therapeutic effects. - Source: PubMed
Publication date: 2026/09/05
Yang WenxiYu GengyuanZhang YananRen DongshengLi YuyingYang JinYao Meicun - To examine the hepatoprotective and antifibrotic properties of Deduhonghua-7 powder and its active component luteolin in a CCl-induced liver fibrosis model, followed by in-depth analysis of the associated molecular mechanisms. - Source: PubMed
Publication date: 2026/09/05
Yumei Anda Xue RunguoHaSi Bai TanaBai YingchunHan Zhiqiang - Obesity reshapes systemic iron handling, yet the resulting iron phenotype is frequently misclassified at the bedside and in population studies. This review examines how excess adiposity disturbs iron metabolism and complicates iron-status assessment, with balanced attention to biology and measurement problems across adults and children. - Source: PubMed
Publication date: 2026/09/05
Aguree SixtusMeng Xiangqi